Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.73 |
| ▸ | PCNA | P12004 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.53 |
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | XIAP | P98170 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11370023 | 1.00 | SLC7A5 (0.73) | SLC7A5PCNAPTPN1PTGS1ALPI | |
| SCHEMBL11520038 | 1.00 | SLC7A5 (0.73) | SLC7A5PCNAPTPN1PTGS1ALPI | |
| SCHEMBL8168147 | 1.00 | SLC7A5 (0.73) | SLC7A5PCNAPTPN1PTGS1ALPI | |
| SCHEMBL1667022 | 1.00 | SLC7A5 (0.73) | SLC7A5PCNAPTPN1PTGS1ALPI | |
| SCHEMBL11676390 | 1.00 | SLC7A5 (0.73) | SLC7A5PCNAPTPN1PTGS1ALPI | |
| SCHEMBL10978818 | 1.00 | SLC7A5 (0.73) | SLC7A5PCNAPTPN1PTGS1ALPI | |
| SCHEMBL17164598 | 0.93 | SLC7A5 (0.63) | SLC7A5PCNAPTPN1PTGS1ALPI | |
| Tyrosine SCHEMBL12471723 | 0.92 | SLC7A5 (0.65) | SLC7A5PCNAPTPN1PTGS1ALPI | |
| Phenylalanine SCHEMBL5608077 | 0.89 | SLC7A5 (0.69) | SLC7A5PTPN1PTGS1ALPIPKM | |
| Phenylalanine SCHEMBL5699042 | 0.89 | SLC7A5 (0.69) | SLC7A5PTPN1PTGS1ALPIPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1000 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024129676-A1 | DOSAGE REGIME OF ORFORGLIPRON FOR TREATING A SUBJECT WITH TYPE 2 DIABETES (T2D), OBESITY, OR OVERWEIGHT WITH AT LEAST ONE WEIGHT RELATED COMORBIDITY | ELI LILLY AND COMPANY (US) | 2024-06-20 | — | — | WO | claimed |
| WO-2023114835-A9 | GENE THERAPIES FOR METABOLIC DISORDERS | FRACTYL HEALTH, INC. (US) | 2024-06-06 | — | — | WO | claimed |
| WO-2024091863-A1 | COMBINATORIAL, AND ROTATIONAL COMBINATORIAL THERAPIES FOR OBESITY AND OTHER DISEASES | STARROCK PHARMA LLC (US) | 2024-05-02 | — | — | WO | claimed |
| EP-4341218-A1 | ASSESSING AND TREATING OBESITY | Mayo Foundation for Medical Education and Research (US) | 2024-03-27 | — | — | EP | claimed |
| WO-2024050289-A1 | COMPOSITIONS FOR ORAL DELIVERY | ELI LILLY AND COMPANY (US) | 2024-03-07 | — | — | WO | claimed |
| WO-2023220618-A1 | INDIVIDUALIZED LIFESTYLE INTERVENTION FOR OBESITY MANAGEMENT BASED ON OBESITY PHENOTYPES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2023-11-16 | — | — | WO | claimed |
| US-20230358765-A1 | METHODS AND MATERIALS FOR ASSESSING AND TREATING OBESITY | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2023-11-09 | — | — | US | claimed |
| US-20230355563-A1 | HUNGER SUPPRESSION | TDELTAS LIMITED (GB) | 2023-11-09 | — | — | US | claimed |
| WO-2023114835-A1 | GENE THERAPIES FOR METABOLIC DISORDERS | FRACTYL HEALTH, INC. (US) | 2023-06-22 | — | — | WO | claimed |
| EP-4194001-A1 | ENTERICALLY DELIVERED BITTER OLIGOPEPTIDES FOR THE TREATMENT FOR TYPE 2 DIABETES AND OBESITY | Cedars-Sinai Medical Center (US) | 2023-06-14 | — | — | EP | claimed |
| WO-2007021970-A2 | STABLE PHARMACEUTICAL FORMULATIONS AND METHODS OF USE THEREOF | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | WO | claimed |
| WO-2006126208-A2 | COMPOSITIONS AND METHODS USING SAME FOR DELIVERING AGENTS INTO A TARGET ORGAN PROTECTED BY A BLOOD BARRIER | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-11-30 | — | — | WO | claimed |
| US-20060193825-A1 | Pharmaceutical formulations for sustained drug delivery | PRAECIS PHAMACEUTICALS, INC. (US) | 2006-08-31 | — | — | US | claimed |
| WO-2006041538-A2 | A MIXTURE FOR TRANSDERMAL DELIVERY OF LOW AND HIGH MOLECULAR WEIGHT COMPOUNDS | ORYXE (US) | 2006-04-20 | — | — | WO | claimed |
| US-6440691-B1 | AIDS VIRICIDES | LARGE SCALE BIOLOGY CORPORATION | 2002-08-27 | — | — | US | claimed |
| US-20020039726-A1 | Melanins with improved ability to inhibit HIV replication | GARGER STEVEN (US) | 2002-04-04 | — | — | US | claimed |
| US-6300057-B1 | TREATING HIV INFECTIONS BY ADMINISTERING A THERAPEUTIC DOSE OF SYNTHESIZED MELANIN CONTAINING AN ANIONIC GROUP OF SULFATES AND SULFONYLS; NONTOXIC THERAPY OF HUMAN IMMUNODEFICIENCY VIRUS | LARGE SCALE BIOLOGY CORPORATION | 2001-10-09 | — | — | US | claimed |
| EP-1095652-A2 | Melanins with improved ability to inhibit HIV replication | Biosource Technologies, Inc. (US) | 2001-05-02 | — | — | EP | claimed |
| EP-1014964-A1 | MELANINS WITH IMPROVED ABILITY TO INHIBIT HIV REPLICATION | Biosource Technologies, Inc. (US) | 2000-07-05 | — | — | EP | claimed |
| WO-1998034606-A1 | MELANINS WITH IMPROVED ABILITY TO INHIBIT HIV REPLICATION | BIOSOURCE TECHNOLOGIES, INC. (US) | 1998-08-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355563-A1 | HUNGER SUPPRESSION | CCKBR, GHSR, GPR119 | SLC7A5 1001/4885PCNA 2117/4885PTPN1 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.